Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

妥珠单抗 医学 安慰剂 类风湿性关节炎 内科学 甲氨蝶呤 痹症科 随机对照试验 胃肠病学 关节炎 外科 阿达木单抗 病理 替代医学
作者
Edward Keystone,Désirée van der Heijde,David Mason,Robert Landewé,Ronald van Vollenhoven,Bernard Combe,Paul Emery,Vibeke Strand,Philip J. Mease,Chintu Desai,Karel Pavelká
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:58 (11): 3319-3329 被引量:574
标识
DOI:10.1002/art.23964
摘要

Abstract Objective To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti–tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone. Methods In this 52‐week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous certolizumab pegol at an initial dosage of 400 mg given at weeks 0, 2, and 4, with a subsequent dosage of 200 mg or 400 mg given every 2 weeks, plus MTX, or placebo plus MTX. Co‐primary end points were the response rate at week 24 according to the American College of Rheumatology 20% criteria for improvement (ACR20) and the mean change from baseline in the modified total Sharp score at week 52. Results At week 24, ACR20 response rates using nonresponder imputation for the certolizumab pegol 200‐mg and 400‐mg groups were 58.8% and 60.8%, respectively, as compared with 13.6% for the placebo group. Differences in ACR20 response rates versus placebo were significant at week 1 and were sustained to week 52 ( P < 0.001). At week 52, mean radiographic progression from baseline was reduced in patients treated with certolizumab pegol 200 mg (0.4 Sharp units) or 400 mg (0.2 Sharp units) as compared with that in placebo‐treated patients (2.8 Sharp units) ( P < 0.001 by rank analysis). Improvements in all ACR core set of disease activity measures, including physical function, were observed by week 1 with both certolizumab pegol dosage regimens. Most adverse events were mild or moderate. Conclusion Treatment with certolizumab pegol 200 or 400 mg plus MTX resulted in a rapid and sustained reduction in RA signs and symptoms, inhibited the progression of structural joint damage, and improved physical function as compared with placebo plus MTX treatment in RA patients with an incomplete response to MTX.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wonder123发布了新的文献求助10
2秒前
Rainnnn完成签到,获得积分10
3秒前
3秒前
麦子发布了新的文献求助10
5秒前
秋白完成签到 ,获得积分10
7秒前
wanci应助家伟采纳,获得10
7秒前
9秒前
情怀应助杜兰特采纳,获得20
9秒前
9秒前
bbh发布了新的文献求助30
10秒前
冷静的无颜完成签到,获得积分10
10秒前
Maxine完成签到 ,获得积分10
10秒前
搜集达人应助qls123采纳,获得10
10秒前
禾苗完成签到 ,获得积分10
12秒前
爆米花应助zhq采纳,获得10
13秒前
13秒前
14秒前
Liufgui应助杨桃采纳,获得10
14秒前
16秒前
congenialboy发布了新的文献求助10
16秒前
yar应助易安采纳,获得30
19秒前
19秒前
家伟发布了新的文献求助10
19秒前
Lucas应助怕孤单的破茧采纳,获得10
20秒前
20秒前
wonder123发布了新的文献求助10
20秒前
大猫应助KK采纳,获得10
20秒前
20秒前
22秒前
微笑的语芙完成签到,获得积分10
23秒前
25秒前
灵巧妙柏发布了新的文献求助10
25秒前
CipherSage应助好滴捏采纳,获得10
26秒前
香云完成签到 ,获得积分10
26秒前
27秒前
搜集达人应助艺涵采纳,获得10
28秒前
M_a完成签到,获得积分10
29秒前
mm驳回了华仔应助
29秒前
30秒前
bbh完成签到,获得积分10
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989550
求助须知:如何正确求助?哪些是违规求助? 3531774
关于积分的说明 11254747
捐赠科研通 3270278
什么是DOI,文献DOI怎么找? 1804966
邀请新用户注册赠送积分活动 882125
科研通“疑难数据库(出版商)”最低求助积分说明 809176